Key facts
- CBio (Biotechnology)’s last known valuation is $5.8M (Jan 2026).
- It has raised $2.0M; the latest was PE Growth/Expansion ($440K) in Jan 2026.
- Notable investors include Capital Factory, United States Department of War, Telescopic Ventures, LEONID, Magnify — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for CBio (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for CBio (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CBio (Biotechnology)
Developer of analytical tools intended to support cell and viral vector gene therapy quality testing. The company's tools offer an accurate and rapid assessment of microbial contamination, detection of empty virus particles and other emerging quality issues affecting cell and gene therapy bio-manufacturing and delivery, enabling pharmaceutical and drug manufacturing companies to ensure life-saving treatments will work as expected and are safe for patients to receive.
- Sector
- Healthcare
- HQ
- Irvine, CA, United States
- Founded
- 2016
- Employees
- 4
- Website
- cbio.io/
- Ownership
- Privately Held (backing)
CBio (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CBio (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CBio (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.